Abstract:Background: Endogenous insulin supplementation is essential for individuals with type 1 diabetes (T1D). However, current treatments, including pancreas transplantation, insulin injections, and oral medications, have significant limitations. The development of engineered cells that can secrete endogenous insulin offers a promising new therapeutic strategy for type 1 diabetes (T1D). This approach could potentially circumvent autoimmune responses associated with the transplantation of differentiated β-cells or systemic delivery of viral vectors. Methods: We utilized CRISPR/Cas9 gene editing coupled with homology-directed repair (HDR) to precisely integrate a promoter-free EMCVIRES-insulin cassette into the 3' untranslated region (UTR) of the GAPDH gene in human HEK-293T cells. Subsequently quantified insulin expression levels in these engineered cells, the viability and functionality of the engineered cells when seeded on different cell vectors (GelMA and Cytopore I) were also assessed. Finally, we investigated the therapeutic potential of EMCVIRES-based insulin secretion circuits in reversing Hyperglycaemia in T1D mice. Result: Our results demonstrate that HDR-mediated gene editing successfully integrated the IRES-insulin loop into the genome of HEK-293T cells, a non-endocrine cell line, enabling the expression of human-derived insulin. Furthermore, Cytopore I microcarriers facilitated cell attachment and proliferation during in vitro culture and enhanced cell survival post-transplantation. Transplantation of these cell-laden microcarriers into mice led to the development of a stable, fat-encapsulated structure. This structure exhibited the expression of the platelet-endothelial cell adhesion molecule CD31, and no significant immune rejection was observed throughout the experiment. Diabetic mice that received the cell carriers reversed hyperglycemia, and blood glucose fluctuations under simulated feeding stimuli were very similar to those of healthy mice. Conclusion: In summary, our study demonstrates that Cytopore I microcarriers are biocompatible and promote long-term cell survival in vivo. The promoter-free EMCVIRES-insulin loop enables non-endocrine cells to secrete mature insulin, leading to a rapid reduction in glucose levels. We have presented a novel promoter-free genetic engineering strategy for insulin secretion and proposed an efficient cell transplantation method. Our findings suggest the potential to expand the range of cell sources available for the treatment of diabetes, offering new avenues for therapeutic interventions.

Genetically reprogrammed, liver-derived insulin-producing cells are glucose-responsive, but susceptible to autoimmune destruction in settings of murine model of type 1 diabetes.

Insulin-Producing Cells from Human Pancreatic Islet-Derived Progenitor Cells Following Transplantation in Mice

In vivo direct reprogramming of liver cells to insulin producing cells by virus-free overexpression of defined factors.

Direct Reprogramming of Hepatocytes into Insulin-Producing Cells for Anti-Diabetic Treatment by Ultrasound-Targeted Microbubble Destruction Enhanced Hydrodynamic Gene Delivery

The future treatment for type 1 diabetes: Pig islet- or stem cell-derived β cells?

Ex Vivo Expanded Human Regulatory T Cells Delay Islet Allograft Rejection Via Inhibiting Islet-Derived Monocyte Chemoattractant Protein-1 Production in CD34+ Stem Cells-Reconstituted NOD-scid IL2rγnull Mice.

Differentiation and Transplantation of Functional Pancreatic Beta Cells Generated from Induced Pluripotent Stem Cells Derived from a Type 1 Diabetes Mouse Model

Endogenous Reprogramming of Alpha Cells into Beta Cells, Induced by Viral Gene Therapy, Reverses Autoimmune Diabetes

Reprogramming liver-stem WB cells into functional insulin-producing cells by persistent expression of Pdx1- and Pdx1-VP16 mediated by lentiviral vectors

High Glucose is Necessary for Complete Maturation of Pdx1-VP16-expressing Hepatic Cells into Functional Insulin-Producing Cells.

The reprogrammed pancreatic progenitor-like intermediate state of hepatic cells is more susceptible to pancreatic beta cell differentiation.

Generation of iPSC-derived insulin-producing cells from patients with type 1 and type 2 diabetes compared with healthy control

Specific Reprogramming of Alpha Cells to Insulin-Producing Cells by Short Glucagon Promoter-Driven Pdx1 and MafA

Long-term Tolerance to Islet Transplantation via Targeted Reduction of beta cell-specific T cells.

Immunoprotection Strategies in β‐Cell Replacement Therapy: A Closer Look at Porcine Islet Xenotransplantation

Engineered IRES-mediated promoter-free insulin-producing cells reverse hyperglycemia

Type 1 diabetes induction in humanized mice.

Inducing Specific Immune Tolerance to Prevent Type 1 Diabetes in NOD Mice.

Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation

An altered CD8 + T cell epitope of insulin prevents type 1 diabetes in humanized NOD mice

Correction of Hyperglycemia in Type 1 Diabetic Models by Transplantation of Encapsulated Insulin-Producing Cells Derived from Mouse Embryo Progenitor